From breaking bad to worse: Exploiting homologous DNA repair deficiency in cancer

Cancer Discovery

Volumn 4, Issue 5, 2014, Pages 516-518

  Hemann, Michael T ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; FANCONI ANEMIA GROUP D2 PROTEIN; PROTEIN MSH3; PROTEIN P53; RAD50 PROTEIN; ANTINEOPLASTIC AGENT; DNA LIGASE;

ARTICLE; CELL CYCLE PARAMETERS; DISORDERS OF DNA SYNTHESIS AND REPAIR; DNA DAMAGE; DNA END JOINING REPAIR; GENE EXPRESSION; GENE MUTATION; GENOME ANALYSIS; GENOMIC INSTABILITY; HOMOLOGOUS RECOMBINATION; HUMAN; NEOPLASM; RNA INTERFERENCE; SIGNAL TRANSDUCTION; DRUG EFFECTS; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; RECOMBINATION REPAIR;

ANTINEOPLASTIC AGENTS; DNA REPAIR ENZYMES; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; RECOMBINATIONAL DNA REPAIR;

EID: 84899678913     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-14-0316     Document Type: Article

References (10)

1. Reinhardt HC, Jiang H, Hemann MT, Yaffe MB. Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle 2009; 8: 3112-9.
2. Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, et al. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev 2009; 23: 1895-909.
3. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB. p53-deficient cells rely on ATM-and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 2007; 11: 175-89.
4. Mukhopadhyay UK, Senderowicz AM, Ferbeyre G. RNA silencing of checkpoint regulators sensitizes p53-defective prostate cancer cells to chemotherapy while sparing normal cells. Cancer Res 2005; 65: 2872-81.
5. Origanti S, Cai SR, Munir AZ, White LS, Piwnica-Worms H. Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells. Oncogene 2013; 32: 577-88.
6. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-21.
7. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-7.
8. Dietlein F, Thelen L, Jokic M, Jachimowicz RD, Ivan L, Knittel G, et al. A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC. Cancer Discov 2014;4:592-605.
9. Riabinska A, Daheim M, Herter-Sprie GS, Winkler J, Fritz C, Hallek M, et al. Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors. Sci Transl Med 2013; 5: 189ra78.
10. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-7.